Home › Companies › Krystal Biotech, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Krystal Biotech, Inc.’s Form 8-K, filed 2026-05-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Krystal Biotech, Inc. in the interactive database Compare manager voting policies
These tallies are Krystal Biotech, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Krish S. Krishnan | 23,802,920 | -- | -- | 3,079,194 | 1,581,473 | Majority: yes |
| Elect Director: Christopher Mason | 22,581,854 | -- | -- | 4,300,260 | 1,581,473 | Majority: yes |
| Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year en | 28,443,155 | 15,434 | 4,998 | -- | -- | Majority: yes |
| Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for the fiscal year ended | 25,679,318 | 1,195,788 | 7,008 | -- | 1,581,473 | Majority: yes |
| Proposal Four: Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the the Company's board of directors and the defendants in the litigation entitled Corbin v. Janney, et al. | 21,374,021 | 2,349,550 | 3,158,543 | -- | 1,581,473 | Majority: yes |
Source: Krystal Biotech, Inc., Form 8-K, filed with the SEC on 2026-05-20 — read the filing on EDGAR.
Each item below shows how the 372 asset managers that disclosed a Krystal Biotech, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Krystal Biotech, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 11 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Krystal Biotech, Inc.’s own tally for this item (“Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for t”): 25,679,318 for, 1,195,788 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,437,000 outstanding shares: 87% for, 4% against (91% of the company cast a for/against vote).
The 370 asset managers below cast 93% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,891,795 | 0 | 0 | 0 | For |
| BlackRock | 3,009,417 | 11,386 | 0 | 0 | For |
| Vanguard | 2,901,273 | 3 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,542,298 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,578,940 | 0 | 0 | Against |
| State Street | 1,132,447 | 5,274 | 0 | 0 | For |
| T. Rowe Price | 884,203 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 673,505 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 617,871 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 565,170 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 481,307 | 0 | 0 | 0 | For |
| Charles Schwab | 452,541 | 0 | 0 | 0 | For |
| Invesco | 390,384 | 13 | 0 | 0 | For |
| First Trust | 352,157 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 319,160 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 201,001 | 0 | 0 | 0 | For |
| Nuveen | 185,361 | 0 | 0 | 0 | For |
| Northern Trust | 178,067 | 2,506 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 175,358 | 0 | 0 | 0 | For |
| Voya | 164,862 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 161,116 | 0 | 0 | 0 | For |
| Woodline Partners LP | 150,616 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| Dimensional | 117,292 | 0 | 0 | 0 | For |
Showing the 25 largest of 370 asset managers. See all 370 in the interactive database.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Krystal Biotech, Inc.’s own tally for this item (“Proposal Four: Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the the Company's board of directors and the defendants in the litigation entitled Corbin v”): 21,374,021 for, 2,349,550 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,437,000 outstanding shares: 73% for, 8% against (81% of the company cast a for/against vote).
The 125 asset managers below cast 91% of the shares they voted on this item FOR (12,033,524 for, 1,254,817 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,680,646 | 3,724 | 10 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 0 | 755,181 | 0 | 0 | Against |
| State Street | 696,408 | 221 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 481,307 | 0 | 0 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 349,271 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 211,339 | 0 | 0 | Against |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 0 | 150,000 | 0 | 0 | Against |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 91,520 | 0 | 0 | 0 | For |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 63,334 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 0 | 62,845 | 0 | 0 | Against |
| Jackson National | 58,432 | 0 | 0 | 0 | For |
| Dimensional | 51,803 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 48,180 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 35,641 | 0 | 0 | 0 | For |
| Victory Capital | 34,820 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,952 | 0 | 0 | 0 | For |
Showing the 25 largest of 125 asset managers. See all 125 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Krystal Biotech, Inc.’s own tally for this item (“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm fo”): 28,443,155 for, 15,434 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,437,000 outstanding shares: 97% for, 0.1% against (97% of the company cast a for/against vote).
The 109 asset managers below cast 99.9% of the shares they voted on this item FOR (12,758,624 for, 10,466 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,684,382 | 0 | 0 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 696,629 | 0 | 0 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 349,271 | 0 | 0 | 0 | For |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 91,520 | 0 | 0 | 0 | For |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 63,334 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 58,432 | 0 | 0 | 0 | For |
| Dimensional | 51,803 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 48,180 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 35,641 | 0 | 0 | 0 | For |
| Victory Capital | 34,820 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,952 | 0 | 0 | 0 | For |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.
Combines 7 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Krystal Biotech, Inc.’s own tally for this item (“Elect Director: Christopher Mason”): 22,581,854 for, 4,300,260 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,437,000 outstanding shares: 77% for, 15% withheld (91% of the company cast a for/withheld vote).
The 105 asset managers below cast 100% of the shares they voted on this item FOR (11,055,090 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,684,367 | 0 | 15 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 1,684 | 0 | 694,945 | 0 | Abstain |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 349,271 | 0 | Abstain |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 0 | 0 | 91,520 | 0 | Abstain |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 43,274 | 0 | 20,060 | 0 | For |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 58,432 | 0 | Abstain |
| Dimensional | 0 | 0 | 51,803 | 0 | Abstain |
| Janus Detroit Street Trust | 0 | 0 | 48,180 | 0 | Abstain |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 6,160 | 0 | 29,481 | 0 | Abstain |
| Victory Capital | 0 | 0 | 34,820 | 0 | Abstain |
| Lincoln Financial | 1,261 | 0 | 27,691 | 0 | Abstain |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.
Combines 7 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Krystal Biotech, Inc.’s own tally for this item (“Elect Director: Krish S. Krishnan”): 23,802,920 for, 3,079,194 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 29,437,000 outstanding shares: 81% for, 10% withheld (91% of the company cast a for/withheld vote).
The 105 asset managers below cast 100% of the shares they voted on this item FOR (11,716,487 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,680,656 | 0 | 3,725 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 695,716 | 0 | 913 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 349,271 | 0 | Abstain |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 0 | 0 | 91,520 | 0 | Abstain |
| Voya | 0 | 0 | 67,317 | 0 | Abstain |
| Equitable | 43,274 | 0 | 20,060 | 0 | For |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 58,432 | 0 | Abstain |
| Dimensional | 0 | 0 | 51,803 | 0 | Abstain |
| Janus Detroit Street Trust | 0 | 0 | 48,180 | 0 | Abstain |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 6,160 | 0 | 29,481 | 0 | Abstain |
| Victory Capital | 0 | 0 | 34,820 | 0 | Abstain |
| Lincoln Financial | 18,007 | 0 | 10,945 | 0 | For |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (6,119 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TEALWOOD ASSET MANAGEMENT INC | 4,564 | 0 | 0 | 0 | For |
| Evolutionary Tree Capital Management, LLC | 1,555 | 0 | 0 | 0 | For |
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (7,608 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Zacks Trust | 7,119 | 0 | 0 | 0 | For |
| SARATOGA ADVANTAGE TRUST | 489 | 0 | 0 | 0 | For |
Ranked by the number of Krystal Biotech, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 29,437,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 26.81% |
| 2 | BlackRock | 10.26% |
| 3 | Vanguard | 9.86% |
| 4 | Avoro Capital Advisors LLC | 8.64% |
| 5 | Capital Group | 5.36% |
| 6 | State Street | 3.86% |
| 7 | T. Rowe Price | 3.00% |
| 8 | Redmile Group, LLC | 2.29% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.10% |
| 10 | Hood River Capital Management LLC | 1.92% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.86% | 13F |
| FMR LLC | 14.58% | DEF14A |
| BlackRock | 13.39% | 13F |
| Krish S. Krishnan | 11.51% | 13G |
| Vanguard Group | 9.44% | 13F |
| Avoro Capital Advisors LLC | 8.72% | DEF14A |
| Suma M. Krishnan | 5.65% | DEF14A |
| State Street | 4.47% | 13F |
| T. Rowe Price | 1.65% | 13F |
| Dimensional Fund Advisors | 1.59% | 13F |
Percentages above are of 29,437,000 shares outstanding, as reported by Krystal Biotech, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Krystal Biotech, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Krystal Biotech, Inc.'s shareholder meeting held 2026-05-15, in the 2025-2026 proxy season, 372 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,246 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval of the compensation of the Company's named executive officers, on a non-binding… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Krystal Biotech, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-20.
Krystal Biotech, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).